Metabolomics, the most recent entry in the omics universe, entails the comprehensive measurement of small molecules in biological samples and of their fluctuations upon pathophysiological alterations or external stimuli. Cancer research is one of the fields where metabolomics has been more extensively applied, concomitantly with the rising appreciation of metabolic reprogramming as a key enabling cancer hallmark. Cancer metabolomics has already allowed several candidate diagnostic biomarkers to be identified in tumor biopsies, as well as in surrounding or circulating body fluids. Additionally, metabolic signatures have been correlated with disease stages and response to treatment. Still, great challenges remain in this respect, such as establishing the specificity of metabolic markers and validating their utility in clinical practice. Metabolomics is also useful in helping elucidate oncogenic mechanisms and their molecular links to cellular metabolic pathways. Indeed, with metabolites being increasingly perceived as bioactive molecules capable of influencing tumorigenesis and disease progression, metabolomics approaches, including stable isotope-resolved metabolomics, emerge as uniquely valuable tools in mechanistic discoveries, especially when combined with other biological assays and computational methods.
For this special issue, we would like to invite research and/or review papers which address the application of metabolomics in cancer research, from biomarker identification and validation to bioactivity screening and targeted mechanistic studies. Works focusing on recent analytical and bioinformatics advances, as well as on integration with other omics data, are also welcome.
1. Peter Adriaensens Biomolecule Design Group, Institute for Materials Research (IMO), Hasselt University, Diepenbeek, Belgium.
2. Gilson C Santos National Center for Nuclear Magnetic Resonance Jiri Jonas (CNRMN), Structural Biology Program, Medical Biochemistry Institute and Center for Structural Biology and Bioimaging I (CENABIO I), Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
3. Nathan Bowen Center for Cancer Research and Therapeutic Development, Department of Biological Sciences, Clark Atlanta University, Atlanta, USA.
4. Brian D Adams HMS Initiative for RNA Medicine and Department of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, USA.
5. Consolato Sergi Stollery Children's Hospital, University of Alberta, Edmonton, Canada.
6. Zi-Wei Dai Department of Pharmacology and Cancer Biology, Duke University, Durham, USA.
7. Ana M Gil Department of Chemistry and CICECO - Aveiro Institute of Materials (CICECO/UA), University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal.
8. M Wasif Saif Zucker School of Medicine at Northwell/Hofstra, Hempstead, New York; Division of Medical Oncology, Northwell Health Cancer Institute, New York, USA.
9. Matthew L Goodwin Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, USA.
10. Thereza Quirico-Santos Programa de Pós-graduação em Ciencia e Biotecnologia, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil.
11. Rosalinda Sorrentino Department of Pharmacy (DIFARMA), University of Salerno, Salerno, Italy.
12. Danny N Dhanasekaran Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA; Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
13. Angelo Paci Université Paris-Saclay, Institut Gustave Roussy, CNRS, Vectorologie et thérapeutiques anticancéreuses, Villejuif, France.
The list is arranged in no particular order and being updated.
Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/JCMT/?IssueId=370
Submission Deadline: 31 Aug 2020
Contacts: Monica Gao, assistant editor, firstname.lastname@example.org